The Journal of Immunology, Vol 153, Issue 11 5026-5037, Copyright © 1994 by American Association of Immunologists

ARTICLES

Tepoxalin, a novel immunosuppressive agent with a different mechanism of action from cyclosporin A

L Zhou, D Ritchie, EY Wang, AG Barbone, D Argentieri and CY Lau
R. W. Johnson Pharmaceutical Research Institute, Ontario, Canada.

Tepoxalin, a compound previously identified as a dual cyclooxygenase/lipoxygenase (CO/LO) inhibitor, is a potent inhibitor of T cell proliferation. Comparing the suppressive effects of tepoxalin and cyclosporin A (CsA) on OKT3-, PMA-, IL-2-, and PMA+ionomycin- induced T cell proliferations revealed marked differences in the mechanism of action between the two compounds. Whereas CsA was most effective in suppressing OKT3-stimulated proliferation, tepoxalin was more potent in inhibiting PMA-, PMA+ionomycin-, and IL-2-induced proliferation. Quantitative PCR (QPCR) assays used to detect cytokine messages showed that tepoxalin blocked IL-2 mRNA transcription in PMA- and PMA+ionomycin-, but not OKT3-stimulated T cells whereas CsA was most potent in inhibiting OKT3-induced IL-2 mRNA induction in these cells. Both tepoxalin and CsA did not inhibit the expression of IL-2R; however, only tepoxalin, but not CsA, inhibited the proliferation of IL- 2-dependent blasts and the transcription of IFN-gamma, an IL-2- dependent target gene. Moreover, addition of exogenous IL-2 restored OKT3-induced proliferation to CsA- but not tepoxalin-treated cells. These data suggest that tepoxalin, but not CsA, suppressed T cell proliferation by inhibiting IL-2-induced signal transduction. Consistent with these findings, tepoxalin, unlike CsA, which was most potent when added at the initiation of OKT3 stimulation, was equally active, regardless of whether it was added at the beginning or 48 h after culture initiation. The difference in mechanism of action between tepoxalin and CsA was confirmed further by the synergistic suppressive effects on T cell proliferation upon co-administration of the two compounds.

This article has been cited by other articles:

				M. G. Brocardo, R. Schillaci, A. Galeano, M. Radrizzani, V. White, A. G. Guerrico, T. A. Santa-Coloma, and A. Roldan Early effects of insulin-like growth factor-1 in activated human T lymphocytes J. Leukoc. Biol., August 1, 2001; 70(2): 297 - 305. [Abstract] [Full Text] [PDF]

				M. A. Iniguez, C. Punzon, and M. Fresno Induction of Cyclooxygenase-2 on Activated T Lymphocytes: Regulation of T Cell Activation by Cyclooxygenase-2 Inhibitors J. Immunol., July 1, 1999; 163(1): 111 - 119. [Abstract] [Full Text] [PDF]

				D. H.S. Lee, J. P. Macintyre, G. R. Taylor, E. Wang, R. K. Plante, S. S.C. Tam, B. L. Pope, and C. Y. Lau Tepoxalin Enhances the Activity of an Antioxidant, Pyrrolidine Dithiocarbamate, in Attenuating Tumor Necrosis Factor alpha -Induced Apoptosis in WEHI 164 Cells J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1465 - 1471. [Abstract] [Full Text]

				M. A. Iniguez, S. Martinez-Martinez, C. Punzon, J. M. Redondo, and M. Fresno An Essential Role of the Nuclear Factor of Activated T Cells in the Regulation of the Expression of the Cyclooxygenase-2 Gene in Human T Lymphocytes J. Biol. Chem., July 28, 2000; 275(31): 23627 - 23635. [Abstract] [Full Text] [PDF]